Rauwolfia serpentina/Indian Snakeroot / ROS Cancer Research Results

RS, Rauwolfia serpentina/Indian Snakeroot: Click to Expand ⟱

Features:

Rauwolfia serpentina - Indian Snakeroot, Sarpagandha

Type: Botanical extract / indole alkaloid-containing medicinal plant

Active Constituents: Reserpine, ajmaline, ajmalicine, serpentine, rescinnamine, and related indole alkaloids.

Function: Rauwolfia serpentina contains pharmacologically active indole alkaloids with effects on monoamine transport, adrenergic signaling, cardiovascular regulation, cell proliferation, apoptosis, and other signaling pathways.

Cancer: Experimental evidence suggests anticancer activity for Rauwolfia-derived alkaloids, particularly reserpine, including inhibition of proliferation, induction of apoptosis, and cell-cycle disruption. Evidence for whole Rauwolfia serpentina extract is more limited than for isolated constituents or other Rauwolfia species, so species-specific attribution should be maintained.

Rauwolfia serpentina — also called Indian snakeroot or Sarpagandha, is a medicinal plant in the Apocynaceae family whose roots contain pharmacologically active monoterpenoid indole alkaloids, most notably reserpine, along with ajmaline, ajmalicine, serpentine, rescinnamine, and related compounds. It is classified as a botanical medicinal product / indole-alkaloid source; Reserpine is the best-characterized constituent and acts primarily as an essentially irreversible vesicular monoamine transporter inhibitor, especially VMAT2, depleting norepinephrine, dopamine, and serotonin from neuronal and sympathetic storage vesicles. Historically, Rauwolfia preparations and reserpine were used as antihypertensive agents. Cancer evidence is substantially stronger for isolated reserpine than for standardized R. serpentina extracts, and results from other Rauvolfia species should not automatically be attributed to R. serpentina.

Primary mechanisms (ranked):

Reserpine-mediated VMAT2 inhibition and depletion of vesicular monoamines, producing sustained sympatholytic and central monoaminergic effects; this is the principal established pharmacological mechanism but is not itself a validated anticancer mechanism.
Mitochondrial apoptosis and loss of mitochondrial membrane potential in cancer cells, with BAX/BCL-2 and caspase-associated apoptotic signaling reported for reserpine.
Cell-cycle arrest and inhibition of DNA synthesis/proliferation, including G2 arrest in androgen-independent prostate cancer cells and G0/G1 arrest in some breast-cancer models.
Suppression of tumor invasion and DNA-repair-associated signaling through modulation of TGF-β-related pathways in experimental oral carcinogenesis.
Hippo/YAP signaling modulation by reserpine, including ↓YAP and ↓BCL-2 with ↑MST1 and ↑BAX in a triple-negative breast-cancer model; this evidence derives from isolated reserpine studied alongside Rauvolfia tetraphylla rather than R. serpentina extract.
ROS modulation is secondary and strongly context-dependent: reserpine increased oxidative stress in one triple-negative breast-cancer model but decreased measured ROS in PC3 prostate cancer cells despite mitochondrial depolarization.

Bioavailability / PK relevance: Reserpine is orally absorbed, widely distributed, crosses the blood-brain barrier and placenta, and accumulates substantially in tissues including adipose tissue. Human pharmacokinetic data indicate biphasic elimination, with an early half-life of approximately 4.5 hours and a terminal phase of approximately 11.3 days; pharmacodynamic effects can therefore persist well beyond plasma exposure. Whole-root preparations have variable alkaloid composition and cannot be assumed pharmacokinetically equivalent to purified reserpine.

In-vitro vs systemic exposure relevance: Anticancer findings are predominantly from cell-culture or animal experiments using purified reserpine or extracts whose achievable human tumor exposure is uncertain. Concentrations producing cancer-cell effects should therefore not be assumed achievable or safe with oral R. serpentina. Chronic pharmacological effects may occur at low systemic reserpine exposure because VMAT binding and monoamine depletion are prolonged, but this does not establish clinically relevant anticancer exposure.

Clinical evidence status: Hypertension: historical controlled human evidence and established pharmacology. Cancer: preclinical only; no established anticancer clinical efficacy. Human studies of Rauwolfia/reserpine primarily concern hypertension rather than cancer. Major constraints include hypotension, bradycardia, CNS monoamine depletion, depression, Parkinsonian/extrapyramidal effects, gastrointestinal hypersecretion, drug interactions, and prolonged pharmacodynamic action. Reserpine-containing labeling also notes animal tumorigenicity and uncertain historical epidemiologic findings concerning breast cancer, making indiscriminate interpretation of reserpine as an anticancer compound inappropriate.

Rauwolfia serpentina Cancer-Relevant Mechanisms

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Mitochondrial apoptosis	↑ apoptosis; ↓ mitochondrial membrane potential; ↑ BAX; ↓ BCL-2	Potential mitochondrial and CNS toxicity at pharmacologic exposure	R/G	Apoptotic cell death	Best demonstrated for isolated reserpine. PC3 prostate-cancer cells show mitochondrial depolarization, DNA fragmentation, and apoptotic changes.
2	Cell cycle and DNA synthesis	↓ proliferation; ↓ DNA synthesis; ↑ cell-cycle arrest	Potential ↓ proliferation in susceptible normal cells (context-dependent)	G	Growth suppression	G2 arrest reported in PC3 cells; G0/G1 accumulation reported in reserpine-treated MDA-MB-231 cells. Phase depends on model.
3	TGF-β signaling and DNA repair	↓ tumor-promoting TGF-β-associated signaling; ↓ DNA repair; ↓ invasion	Uncertain	G	Reduced survival and invasion	Reported in experimental oral carcinogenesis with reserpine. Translation to whole R. serpentina preparations remains unestablished.
4	Hippo YAP signaling	↑ MST1; ↓ LATS1; ↓ YAP; ↓ YAP-TEAD activity; ↑ BAX; ↓ BCL-2	Uncertain	G	↓ proliferation and ↑ apoptosis	Observed with isolated reserpine in MDA-MB-231 cells in a Rauvolfia tetraphylla study. Constituent evidence is relevant to reserpine but should not be presented as direct R. serpentina extract evidence.
5	Migration and invasion	↓ migration; ↓ invasion	Uncertain	G	Reduced metastatic phenotype	Supported by breast-cancer and oral-carcinogenesis models using reserpine.
6	Reactive oxygen species	↑ or ↓ ROS (model-dependent)	Potential oxidative and mitochondrial effects (context-dependent)	R/G	Secondary redox modulation	Not suitable for a simple ROS↑ classification. ROS increased in reserpine-treated MDA-MB-231 cells but decreased in PC3 prostate-cancer cells despite mitochondrial depolarization.
7	VMAT2 and monoamine storage	↓ VMAT-dependent vesicular monoamine storage where expressed	↓ VMAT2 function; ↓ norepinephrine, dopamine and serotonin storage	P/R	Monoamine depletion	Core established pharmacological action of reserpine. Highly relevant to systemic toxicity and pharmacology, but its contribution to most reported anticancer effects is not established.
8	Adrenergic and sympathetic signaling	Potential ↓ adrenergic signaling (context-dependent)	↓ sympathetic tone; ↓ peripheral vascular resistance; ↓ heart rate	R/G	Sympatholytic effect	Major clinically established effect resulting from catecholamine depletion. Anticancer significance remains indirect and unproven.
9	Prolactin signaling	Potential ↑ prolactin-driven signaling in susceptible tumors	↑ prolactin (context-dependent)	G	Potential adverse proliferative signal	Important safety counterpoint. Chronic reserpine increased mammary tumors in rodents, attributed partly to prolactin elevation; relevance to human breast-cancer risk remains uncertain.
10	Clinical Translation Constraint	Preclinical anticancer exposure not clinically validated	↓ blood pressure; bradycardia; CNS monoamine depletion; depression risk; extrapyramidal effects	G	Limits anticancer translation	Whole-root alkaloid composition is variable. Reserpine has prolonged tissue pharmacology and an approximately 11-day terminal elimination phase. No established cancer treatment regimen or human anticancer efficacy exists.

P: 0–30 min R: 30 min–3 hr G: >3 hr

ROS, Reactive Oxygen Species: Click to Expand ⟱

Source: HalifaxProj (inhibit)

Type:

Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)
ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
• Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
• HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
• SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
• AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
• mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
• HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
• Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy

ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination


Item  ROS↑  NRF2  Condition  Mechanism Class  Remarks  

ROS">Piperlongumine
+++  ↓  [D][T]  ROS-dominant
Selective <span class="wphighlight">ROS</span> stressor, Prevents compensatory upregulation of NRF2, ie GSH↓



ROS">Shikonin
+++ ↓/± [D][T] ROS-dominant
<span class="wphighlight">ROS</span> + glycolysis + GPX4 inhibition



ROS">Vitamin K3 (menadione)
+++ ↓ [D] ROS-dominant
Quinone redox cycler; toxicity limits use



ROS">Copper (ionic / nano)
+++ ↓ [Fe][F] ROS-dominant
Fenton-type redox chemistry



ROS">Sodium Selenite
+++ ↓ [D] ROS-dominant
Pro-oxidant, depletes GSH



ROS">Juglone
+++ ↓ [D] ROS-dominant
Strong quinone <span class="wphighlight">ROS</span> chemistry



ROS">Auranofin
+++ ↓ [D] ROS-dominant
TrxR inhibition → redox collapse



ROS">Photodynamic Therapy (PDT)
+++ 0 [L][O₂] ROS-dominant
Singlet oxygen is core cytotoxic mechanism



ROS">Radiotherapy / Radiation
+++ 0 [O₂] ROS-dominant
DNA damage largely via <span class="wphighlight">ROS</span>



ROS">Doxorubicin
+++ ↓ [D] ROS-dominant
Chemo; redox cycling + mitochondrial <span class="wphighlight">ROS</span>



ROS">Cisplatin
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span> contributes to DNA/protein damage



ROS">Salinomycin
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated CSC toxicity



ROS">Artemisinin / DHA
++ ↓ [Fe][T] ROS-dominant
Iron-activated radical generation



ROS">Sulfasalazine
++ ↓ [C][T] ROS-dominant
Ferroptosis; xCT inhibition → lipid <span class="wphighlight">ROS</span>



ROS">FMD / fasting
++ ↓ [M][C][O₂] ROS-dominant
Metabolic stress → mitochondrial <span class="wphighlight">ROS</span>



ROS">Vitamin C (pharmacologic)
++ ↓ [Fe][D] ROS-dominant
Extracellular H₂O₂ at high dose



ROS">Silver nanoparticles
++ ± [F][D] ROS-dominant
<span class="wphighlight">ROS</span> common; selectivity unreliable



ROS">Gambogic acid
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated apoptosis



ROS">Parthenolide
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span> + NF-κB suppression



ROS">Plumbagin
++ ↓ [D] ROS-dominant
Quinone <span class="wphighlight">ROS</span> driver



ROS">Allicin
++ ↓ [D] ROS-dominant
Thiol-reactive oxidative stress



ROS">Ashwagandha (Withaferin A)
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated apoptosis



ROS">Berberine
++ ↓ [D][M] ROS-dominant
Mitochondrial <span class="wphighlight">ROS</span> induction



ROS">PEITC
++ ↓ [D][C] ROS-dominant
GSH depletion + <span class="wphighlight">ROS</span>



ROS">Methionine restriction
+ ↓ [M][C][T] ROS-secondary
Redox vulnerability increased; <span class="wphighlight">ROS</span> indirect



ROS">DCA
+ ± [M][T] ROS-secondary
<span class="wphighlight">ROS</span> via forced OXPHOS



ROS">Capsaicin
+ ± [D][T] ROS-secondary
Ca²⁺ stress → <span class="wphighlight">ROS</span>



ROS">Galloflavin
+ 0 [D] ROS-secondary
<span class="wphighlight">ROS</span> not primary driver



ROS">Piperine
+ ± [D][F] ROS-secondary
Weak <span class="wphighlight">ROS</span> induction



ROS">Propyl gallate
+ ↓ [D] ROS-secondary
Pro-oxidant at high dose



ROS">Scoulerine
+ ? [D][T] ROS-secondary
Sparse <span class="wphighlight">ROS</span> data



ROS">Thymoquinone
± ± [D][T] Dual redox
Antioxidant ↔ pro-oxidant switch



ROS">Emodin
± ± [D][T] Dual redox
Not cancer-exclusive



ROS">Alpha-lipoic acid (ALA)
± ↑ [D][M] NRF2-dominant
Antioxidant at low dose



ROS">Curcumin
± ↑/↓ [D][F] NRF2-dominant
Hormetic redox behavior



ROS">EGCG
± ↑/↓ [D][O₂] NRF2-dominant
Auto-oxidation artifacts common



ROS">Quercetin
± ↑/↓ [D][Fe] NRF2-dominant
GSH-dependent cycling



ROS">Resveratrol
± ↑ [D][M] NRF2-dominant
<span class="wphighlight">ROS</span> only at high dose



ROS">Sulforaphane
± ↑↑ [D] NRF2-dominant
Strong NRF2 activator



ROS">Lycopene
0 ↑ — Antioxidant
Consistently antioxidant



ROS">Rosmarinic acid
0 ↑ — Antioxidant
Primarily antioxidant



ROS">Citrate
0 0 — Neutral
Metabolic; not a <span class="wphighlight">ROS</span> agent

Scientific Papers found: Click to Expand⟱

7375-

RS,

Regulation of hippo signaling mediated apoptosis by Rauvolfia tetraphylla in triple-negative breast cancer

in-vitro,

BC,

MDA-MB-231

eff↝, TumCCA↑, TumCMig↓, ROS↑, BAX↑, Mst1↑, Bcl-2↓, YAP/TEAD↓, LATS1↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↝, 1,
Total Targets: 9

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:441  Target#:275  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

Rauwolfia serpentina/Indian Snakeroot / ROS Cancer Research Results

Rauwolfia serpentina Cancer-Relevant Mechanisms

Pathway results for Effect on Cancer / Diseased Cells:

NA, unassigned(tgid=0) ⓘ

Redox & Oxidative Stress(tgid=1) ⓘ

Cell Death(tgid=5) ⓘ

Cell Cycle & Senescence(tgid=11) ⓘ

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Migration(tgid=13) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Pathway results for Effect on Normal Cells:

Home Page